Beta Bionics Chief Product Officer Mike Mensinger sold 2,650 shares of the company's common stock on October 27, 2026, at $22.00 per share, for a total of $58,300, according to a filing reported by Investing.com. The sale was made under a Rule 10b5-1 trading plan that Mensinger adopted on September 8, 2025. After the sale, he beneficially owns 174,740 shares.

The same report says Beta Bionics (NASDAQ: BBNX) reported third-quarter revenue of a record $35.5 million, up 30% from a year earlier. The company posted an adjusted loss of $0.52 per share, compared with a consensus estimate of a $0.32 loss. It raised its full-year 2026 revenue guidance to $124 million to $126 million.

Truist Securities reiterated a Buy rating with a $28.00 price target, citing strong revenue growth and challenges with gross margins tied to durable medical equipment stocking dynamics. TD Cowen raised its price target to $21.00 from $18.00 and kept a Hold rating. It said third-quarter pump shipments were slightly below expectations, but that revenue performed better than the shipment numbers suggested.

The report adds that the company's Mint patch pump is on track for U.S. commercialization in the first quarter of 2027.